Stock Analysis
Haemonetics Corporation (HAE) Stock Analysis
Haemonetics Corporation (HAE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Haemonetics Corporation (HAE) currently has an AIQ Score of 77/100, indicating a bullish setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 60/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
HAE at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $122.86 |
| AIQ Score | 77/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $5.59B |
| P/E Ratio (TTM) | 53.27 |
| Forward P/E | — |
| EPS (Q2 FY2027) | $1.02 |
| Revenue (Q2 FY2027) | $357.76M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.24 |
| Volume | 486.37K |
| 52-week range | $51.00-$132.00 |
| RSI 14 | 58.75 |
| 50-Day SMA | $113.31 |
| 200-Day SMA | $81.26 |
| Analyst Price Target | $140.17 |
| Next Earnings | Feb 4, 2027 |
HAEHaemonetics Corporation
Healthcare / Medical - Devices
Leader
Sector Leader
Latest quote
- Momentum91
- Value60
- Quality77
- Risk resilience67
- Sentiment—
HAE Stock Analysis Summary
Haemonetics Corporation (HAE) currently has an AIQ Score of 77/100, indicating a bullish setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 60/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, HAE has AIQ Score of 77/100 with Momentum base of 91/100 and fading Value at 60/100. Wait for component alignment before adding exposure.
Momentum (91/100) leads while Value (60/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.60% stock move · HAE classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is HAE Bullish or Bearish Right Now?
HAE currently has a bullish overall setup. Momentum is the strongest factor at 91/100, while Value is weakest at 60/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 77/100.
- - Momentum is constructive at 91/100.
- - Risk Resilience is supportive at 67/100.
- - Price is +8.50% above its 50-day SMA.
- - Analyst target implies +14.09% upside from the latest quote.
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
HAE's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 7 neutral, and 6 sell votes. HAE's 14-day RSI is 58.75, which places the stock in a constructive momentum range. HAE's beta is 0.24, indicating lower market sensitivity than the broad market.
What Changed in HAE?
The largest recent change in HAE is Momentum moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the HAE Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
HAE Decision Framework
Public evidence layers, setup checks, and risk context for Haemonetics Corporation.
Haemonetics Corporation (HAE) Stock Analysis
Haemonetics Corporation has an AIQ Score of 77/100 in a Bullish regime. Momentum is strongest at 91/100. Beta is 0.24, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | HAE is in a Bullish AIQ regime with score 77/100. |
| Signal Conflict | The primary conflict is that momentum leads at 91/100 while value lags at 60/100. |
| Factor Evidence | Momentum 91/100 · Value 60/100 · Quality 77/100 · Risk 67/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 91/100.
Momentum is 91/100 and RSI (14) is 58.7.
HAE is in a Bullish regime at 77/100.
Risk factor is 67/100 with beta 0.24 and annual volatility 41.04%.
Current conflict: momentum leads at 91/100 while value lags at 60/100.
HAE Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
HAE Fundamentals
HAE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
HAE Technical Analysis
HAE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
HAE Stock Catalysts
Track HAE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
HAE Dividend Analysis
HAE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
HAE Financial Data
HAE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
HAE Risk Analysis
HAE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
HAE Stock News
HAE stock news, market tone, recent headlines, and catalyst context.
HAE vs Medical - Devices Peers
Current peer cohort: HAE · IRTC · ITGR · LIVN · NEOG. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| HAE Current stock | 77/100 | 60/100 | 91/100 | 67/100 | 1.35 | 41.04% | Current |
| IRTC iRhythm Technologies, Inc. | 44/100 | 43/100 | 34/100 | 44/100 | -0.91 | 54.02% | HAE vs IRTC |
| ITGR Integer Holdings Corporation | — | — | 85/100 | 80/100 | 2.02 | 31.24% | HAE vs ITGR |
| LIVN LivaNova PLC | 71/100 | 60/100 | 83/100 | 71/100 | 1.38 | 39.16% | HAE vs LIVN |
| NEOG Neogen Corporation | 63/100 | 49/100 | 74/100 | 57/100 | 1.19 | 57.93% | HAE vs NEOG |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for HAE: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 19, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 26, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching HAE
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for HAE
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
HAE Stock FAQ
What is HAE stock price today?
Haemonetics Corporation's current stock price is $122.86. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is HAE bullish or bearish right now?
HAE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is HAE's market cap?
HAE's market cap is $5.59B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is HAE's current P/E ratio?
HAE's current P/E ratio is 53.27 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is HAE's RSI?
HAE's 14-day RSI is 58.75 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is HAE above its 50-day and 200-day moving averages?
HAE is 8.50% from its 50-day SMA and 51.29% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is HAE's next earnings date?
HAE's next earnings date is currently listed as Feb 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does HAE pay a dividend?
HAE's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.